Shots:

• The EC has granted full marketing authorization for Nuvaxovid (NVX-CoV2373), following a positive opinion from the EMA’s CHMP. The vaccine can now be used as a primary series in individuals aged ≥12yrs. and as a booster dose in adults aged ≥18yrs. to prevent COVID-19,
• The P-III trial (PREVENT-19) results demonstrated the safety profile as well as efficacy as a primary series in adults, the immunogenicity and safety as a booster dose in adults, and the efficacy and safety as a primary series in individuals aged ≥12yrs.
• Novavax's Nuvaxovid is authorized for use in 40+ markets globally. The company also plans to file for full approval in the US as well as other markets

Ref: PRNewswire | Image: Novavax

Related News:- Novavax’s Nuvaxovid Receives Expanded Authorization for COVID-19 in Canada

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com